{"schema_version":"secwatch.filing_event.v1","accession":"0001411690-23-000008","form_type":"8-K","ticker":"BNGO","cik":"0001411690","company_name":"Bionano Genomics, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.829173+00:00","generated_at":"2026-06-18T06:52:04.049446+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bionano Q4 revenue $8.2M (+30% YoY); FY2022 rev $27.8M (+55%)","bullets":["Q4 revenue $8.2M, up 30% from Q4 2021; FY2022 revenue $27.8M, up 55% from FY2021.","Installed base of Saphyr systems reached 240 at YE 2022, a 46% increase over 2021.","Acquired Purigen Biosystems to accelerate OGM adoption; deal value not disclosed.","Achieved all 2022 ELEVATE! milestones; next-gen OGM system commercial launch planned H1 2023.","2023 revenue outlook provided but specific guidance range not included in this excerpt."],"urls":{"canonical":"https://secwatch.observer/filing/0001411690-23-000008","json":"https://secwatch.observer/filing/0001411690-23-000008.json","markdown":"https://secwatch.observer/filing/0001411690-23-000008.md","text":"https://secwatch.observer/filing/0001411690-23-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411690/000141169023000008/0001411690-23-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411690/000141169023000008/bngo-20230309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T06:52:04.049446+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26eb171b41c116e3d72e4b9c46e4b2c6eb703017","claim":"Bionano Genomics, Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $8.2 million.","evidence_excerpt":"Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Bionano Genomics Reports Fourth Quarter and Full Year 2022 Results and Provides Revenue Outlook for 2023 • Q4 revenue was $8.2 million , which represents a 30% increase over Q4 2021 • 2022 revenue was $27.8 million , which represents a 55% increase over year end 2021 • Reached installed base of 240 Saphyr®","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000141169023000008/0001411690-23-000008-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$8.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6df21e6ed83d52f5b0d1a52cb803b3a2fa72154d","claim":"Bionano Genomics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $27.8 million.","evidence_excerpt":"Full year 2022 revenue was $27.8 million , an increase of 55% compared to 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000141169023000008/0001411690-23-000008-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$27.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}